Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 33,088 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PLACEBO Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT04294667
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
DZP, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
16 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Repeated Cannabis Administration on Experimental Pain and Abuse Liability

NCT04576507
View directory record Official record
Conditions
Cannabis, Pain, Tolerance, Hyperalgesia
Interventions
Active Cannabis, Placebo Cannabis
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Not applicable Interventional Results available

A Pilot Clinical Trial of Varenicline as a Treatment for Alcohol Dependence

NCT01011907
View directory record Official record
Conditions
Substance Dependence
Interventions
varenicline, placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Emeryville, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Eicosapentaenoic Acid and Protein Modulation to Induce Anabolism in Chronic Obstructive Pulmonary Disease (COPD): Aim 2

NCT01624792
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Muscle Wasting
Interventions
Olive oil, Fish oil, Fish oil and placebo
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 22, 2026, 6:23 PM EDT
Withdrawn Phase 2 Interventional

A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19

NCT04379492
View directory record Official record
Conditions
COVID-19, COVID19, Sars-CoV2, SARS-Cov-2
Interventions
Hydroxychloroquine, Placebo
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Cholinesterase Inhibitor Discontinuation

NCT02248636
View directory record Official record
Conditions
Dementia
Interventions
Cholinesterase inhibitor, Sham discontinuation
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
Little Rock, Arkansas • Boise, Idaho • Bedford, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 22, 2026, 6:23 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage

NCT01878136
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Cerebral Vasospasm, Cerebral Aneurysm, Hydrocephalus
Interventions
Tissue Plasminogen Activator
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 11, 2015 · Synced Oct 22, 2026, 6:23 PM EDT
Completed No phase listed Observational

Nutrition Blood Outcomes Following Tocotrienol N2B

NCT01858311
View directory record Official record
Conditions
Stroke
Interventions
Tocotrienol Capsules, Placebo Vehicle
Dietary Supplement · Other
Lead sponsor
Ohio State University
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 22, 2026, 6:23 PM EDT
Recruiting Phase 3 Interventional

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

NCT06079671
View directory record Official record
Conditions
Locally Advanced Cervical Cancer
Interventions
Volrustomig, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
15 Years and older · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Cranberry Extract Supplementation on Cardiovascular Risk Factors in Obese, Insulin Resistant Humans

NCT02068144
View directory record Official record
Conditions
Insulin Resistance, Atherosclerosis
Interventions
Cranberry Extract, Placebo
Dietary Supplement · Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Trial of Progesterone in Twins and Triplets to Prevent Preterm Birth (STTARS)

NCT00099164
View directory record Official record
Conditions
Preterm Birth, Pregnancy, Multifetal
Interventions
17 alpha-hydroxyprogesterone caproate (17P)
Drug
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
795 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
14
States / cities
Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT

NCT02914509
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Travoprost, Placebo Vehicle
Drug · Other
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
10
States / cities
Artesia, California • Colorado Springs, Colorado • Lakeland, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants

NCT07422298
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986278, Placebo, Moxifloxacin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Phase 1Phase 2 Interventional

A Preliminary Study of Sustained-Release Bupropion for Smoking Cessation in Bipolar Affective Disorder

NCT00593099
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Bupropion, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I

NCT02677298
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxin A, Placebo
Drug
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
784 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • Encino, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Phase 3 Interventional Results available

Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007

NCT03853798
View directory record Official record
Conditions
Pyruvate Kinase Deficiency
Interventions
Mitapivat
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
12
States / cities
Phoenix, Arizona • Oakland, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Phase 1 Interventional

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia

NCT02720263
View directory record Official record
Conditions
Schizophrenia
Interventions
ASP4345, Matching Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 22, 2026, 6:23 PM EDT
Terminated Phase 2 Interventional

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )

NCT04426201
View directory record Official record
Conditions
COVID-19, Lymphocytopenia
Interventions
CYT107, Placebo
Drug
Lead sponsor
Revimmune
Industry
Eligibility
25 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate SAGE-324 in Participants With Essential Tremor

NCT05173012
View directory record Official record
Conditions
Essential Tremor
Interventions
SAGE-324, SAGE-324 Matched Placebo
Drug
Lead sponsor
Sage Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
51
States / cities
Hoover, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Calcium: Magnesium Balance, Microbiota, and Necroptosis and Inflammation

NCT04229992
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Magnesium glycinate, Placebo
Dietary Supplement
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 85 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 22, 2026, 6:23 PM EDT
Recruiting Phase 1 Interventional

Study of NTX-2001 on Alcohol Consumption in Alcohol Use Disorder

NCT07520292
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
NTX-2001, Placebo
Drug
Lead sponsor
Newleos Therapeutics, Inc.
Industry
Eligibility
21 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 22, 2026, 6:23 PM EDT
Terminated Phase 4 Interventional Results available

Brief Intervention to Reduce Fear of Public Speaking

NCT02790736
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
propranolol, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 22, 2026, 6:23 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Does a ThoracoLumbar Interfacial Plane (TLIP) Block With Liposomal Bupivacaine Provide TLIP Block in Spinal Surgery

NCT04865211
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Liposomal bupivacaine, Bupivacaine Injection, Placebo
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Phase 4 Interventional Results available

Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms

NCT00332644
View directory record Official record
Conditions
Nicotine Dependence
Interventions
nicotine patch, nicotine lozenge, nicotine patch + nicotine lozenge, bupropion, bupropion + lozenge, placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
1,504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Oct 22, 2026, 6:23 PM EDT